Clinical Trial Update: A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating reversibility of CNS-related neurotoxicity after switching to a darunavir/cobicistat-based regimen in people with HIV; completed study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• TAF/FTC/DRV/c (tenofovir alafenamide / emtricitabine / darunavir / cobicistat)

Snippet

Sponsor: Fundacion SEIMC-GESIDA | Conditions: HIV Infections | Phase 4 | Status: COMPLETED